Abstract: The current invention relates to the use of a physiologically acceptable organic and/or inorganic vanadium compound or complex, such as for example bis(maltolato)oxovanadium (BMOV) in the prevention or amelioration of stress-induced metabolic derangement in a subject. More in particular, the invention relates to a physiologically acceptable organic and/or inorganic vanadium compound or complex for use in the amelioration of hyperglycemia in a subject suffering from stress such as elicited by a trauma, wherein the physiologically acceptable organic and/or inorganic vanadium compound or complex is administered to said subject before the trauma is inflicted to the subject.

Abstract: The invention relates to floating drug delivery systems (FDDS) that provide solutions to the particular problems often encountered with floating drug delivery systems described in the art. On such generally recognized problem is the vulnerability of the systems, especially damage to the gas-filled compartment making it accessible to water so as to impair its buoyancy, ultimately resulting in insufficient gastric residence time. The invention, in an aspect, provides a self-repairing FDDS that maintains its floating capacity after damaging. The floating drug delivery systems of the invention, furthermore, allow for incorporation of high loads of active ingredients. The floating drug delivery systems can be designed in such a way that release of active ingredient from the system occurs entirely independent from the pH of the fluid surrounding the system.

Abstract: The present invention relates to a method for maintaining normoglycemia in a mammal in need thereof, preferably a critically ill patient suffering from acute stress, and to a method for preventing or limiting renal ischemia-reperfusion (I/R) in a mammal, preferably in a critically ill patient suffering from acute stress.

Abstract: The present invention relates to a method for maintaining normoglycemia in a mammal in need thereof, preferably a critically ill patient suffering from acute stress, and to a method for preventing or limiting renal ischemia-reperfusion (I/R) in a mammal, preferably in a critically ill patient suffering from acute stress.

Abstract: The present invention relates to compositions and methods for the prophylaxis or treatment of deficiencies in essential amino acid absorption and metabolism and/or of a pathology or symptom associated there with. In particular the invention concerns the treatment and/or prevention of ADHD, ADD and autism spectrum disorders. The present inventors have developed a method for prophylaxis or treatment of such symptoms and/or pathologies associated with a deficiency in essential amino acid absorption and/or metabolism, which method, stated generally, relies on the administration of nicotinamide, typically in a long-acting formulation so as to overcome the deficiencies of existing formulations, which have proven unsuitable for effective treatment.

Abstract: The current invention relates to the use of a physiologically acceptable organic and/or inorganic vanadium compound or complex, such as for example bis(maltolato)oxovanadium (BMOV) in the prevention or amelioration of stress-induced metabolic derangement in a subject. More in particular, the invention relates to a physiologically acceptable organic and/or inorganic vanadium compound or complex for use in the amelioration of hyperglycemia in a subject suffering from stress such as elicited by a trauma, wherein the physiologically acceptable organic and/or inorganic vanadium compound or complex is administered to said subject before the trauma is inflicted to the subject.

Abstract: The present invention relates to a method for maintaining normoglycemia in a mammal in need thereof, preferably a critically ill patient suffering from acute stress, and to a method for preventing or limiting renal ischemia-reperfusion (I/R) in a mammal, preferably in a critically ill patient suffering from acute stress.

Abstract: The present invention relates to compositions and methods for the prophylaxis or treatment of deficiencies in essential amino acid absorption and metabolism and/or of a pathology or symptom associated there with. In particular the invention concerns the treatment and/or prevention of ADHD, ADD and autism spectrum disorders. The present inventors have developed a method for prophylaxis or treatment of such symptoms and/or pathologies associated with a deficiency in essential amino acid absorption and/or metabolism, which method, stated generally, relies on the administration of nicotinamide, typically in a long-acting formulation so as to overcome the deficiencies of existing formulations, which have proven unsuitable for effective treatment.

Abstract: The invention relates to floating drug delivery systems (FDDS) that provide solutions to the particular problems often encountered with floating drug delivery systems described in the art. On such generally recognized problem is the vulnerability of the systems, especially damage to the gas-filled compartment making it accessible to water so as to impair its buoyancy, ultimately resulting in insufficient gastric residence time. The invention, in an aspect, provides a self-repairing FDDS that maintains its floating capacity after damaging. The floating drug delivery systems of the invention, furthermore, allow for incorporation of high loads of active ingredients. The floating drug delivery systems can be designed in such a way that release of active ingredient from the system occurs entirely independent from the pH of the fluid surrounding the system.

Abstract: The invention relates to floating drug delivery systems(FDDS) that provide solutions to the particular problems often encountered with floating drug delivery systems described in the art. On such generally recognized problem is the vulnerability of the systems, especially damage to the gas-filled compartment making it accessible to water so as to impair its buoyancy, ultimately resulting in insufficient gastric residence time. The invention, in an aspect, provides a self-repairing FDDS that maintains its floating capacity after damaging. The floating drug delivery systems of the invention, furthermore,allow for incorporation of high loads of active ingredients. The floating drug delivery systems can be designed in such a way that release of active ingredient from the system occurs entirely independent from the pH of the fluid surrounding the system.

Abstract: The present invention relates to compositions and methods for the prophylaxis or treatment of deficiencies in essential amino acid absorption and metabolism and/or of a pathology or symptom associated there with. In particular the invention concerns the treatment and/or prevention of ADHD, ADD and autism spectrum disorders. The present inventors have developed a method for prophylaxis or treatment of such symptoms and/or pathologies associated with a deficiency in essential amino acid absorption and/or metabolism, which method, stated generally, relies on the administration of nicotinamide, typically in a long-acting formulation so as to overcome the deficiencies of existing formulations, which have proven unsuitable for effective treatment.

Abstract: The present invention relates to a method for maintaining normoglycemia in a mammal in need thereof, preferably a critically ill patient suffering from acute stress, and to a method for preventing or limiting renal ischemia-reperfusion (I/R) in a mammal, preferably in a critically ill patient suffering from acute stress.

Abstract: The present invention relates to stabilised liquid oxygen releasing composition comprising a component (a) selected from the salts consisting of cations An+ and anions derived from halogen oxides according to the general formula [OmX]? wherein A is a metal selected from Groups 1 or 2 of the Periodic System of the Elements, X is a halogen atom, m=1-4, n=1 or 2, a component (b) selected from the group of oxygen donors, a component (c) selected from the group of oxygen donor stabilising agents and a component (d) selected from the group of liquid binders. The stabilised liquid oxygen releasing composition can be used in pharmaceutical compositions, cosmetic compositions and food applications, e.g. skin care products, dental care products, tooth whitening products including chewing gums.

Abstract: The invention discloses the use of a liquid composition, capable of promoting the growth of tissue cells at the site of a wound, a process that promotes regeneration of tissue and wound healing. More particularly, the present invention relates to the use of a liquid composition comprising a component (a) selected from the salts consisting of cations An+ and anions derived from halogen oxides according to the general formula [OmX]?, a component (b) selected from the group of oxygen donors, and a component (d) selected from the group of liquid binders for the treatment of open wounds and burns.